A Report of the Telepsychiatric Evaluation of SARS-CoV-2 Patients

Zarghami, Arman; Farjam, Mojtaba; Fakhraei, Bahareh; Hashemzadeh, Kosar; Yazdanpanah, Mohammad Hosein

doi:10.1089/tmj.2020.0125

Cited by 40 publications

(49 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty-seven (87%) studies 43,44,[70][71][72][73][85][86][87][88][89][90][91][92][93][94][96][97][98][99][100][101][102][103][104][105]107 were conducted in China, and the remaining four studies were, respectively, conducted in Italy, 75 Ecuador, 95 Turkey, 74 and Iran. 106 Twenty-eight (90%) studies were cross-sectional studies, 43,44,[70][71][72][73][74][75][85][86][87][88]90,[92][93][94][95][96][97][98]…”

Section: Study Characteristicsmentioning

confidence: 99%

“…The median NOS was 3 (range 2-4). Twelve (39%) studies 43,44,72,73,75,85,92,93,95,96,105,106 had a high risk of bias (quality score <3), and 19 (61%) studies 70,71,74,86,[88][89][90][91]94,[97][98][99][100][101][102][103][104]107,108 had a low risk of bias (quality score ≥3). While a majority of the studies employed appropriate statistical methods, used validated screening tools, and had low nonrespondent rates, very few studies justified their choice of sample size or used random sampling.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…There were significant subgroup differences between different screening tool subgroups (P < 0.01). Nineteen studies, 43,44,85,[87][88][89][92][93][94][95][96][98][99][100][101][104][105][106][107] using validated screening tools, yielded a pooled depression prevalence of 45% (95% CI: 36-54%, I 2 = 96%). Four studies, 70,71,73,75 using unvalidated screening tools, reported a pooled prevalence of 47% (95% CI: 15-80%, I 2 = 97%).…”

Section: The Pooled Prevalence Of Depressionmentioning

confidence: 99%

“…Subgroup data by gender were reported by nine studies 70,73,75,94,98,100,101,106,108 for depression prevalence, with a pooled prevalence of 39% for male and 50% for female patients (see Fig S15, online only). Eight studies 70,73,75,94,98,101,106,108 reported subgroup data for anxiety prevalence, with a pooled prevalence of 35% for males and 49% for females (see Fig. S16, online only).…”

Section: Subgroup Analysesmentioning

confidence: 99%

See 3 more Smart Citations

The prevalence of depression, anxiety, and sleep disturbances in COVID‐19 patients: a meta‐analysis

Deng

Zhou

Hou

et al. 2020

Annals of the New York Academy of Sciences

630

499

View full text Add to dashboard Cite

Evidence from previous coronavirus outbreaks has shown that infected patients are at risk for developing psychiatric and mental health disorders, such as depression, anxiety, and sleep disturbances. To construct a comprehensive picture of the mental health status in COVID-19 patients, we conducted a systematic review and randomeffects meta-analysis to assess the prevalence of depression, anxiety, and sleep disturbances in this population. We searched MEDLINE, EMBASE, PubMed, Web of Science, CINAHL, Wanfang Data, Wangfang Med Online, CNKI, and CQVIP for relevant articles, and we included 31 studies (n = 5153) in our analyses. We found that the pooled prevalence of depression was 45% (95% CI: 37-54%, I 2 = 96%), the pooled prevalence of anxiety was 47% (95% CI: 37-57%, I 2 = 97%), and the pooled prevalence of sleeping disturbances was 34% (95% CI: 19-50%, I 2 = 98%). We did not find any significant differences in the prevalence estimates between different genders; however, the depression and anxiety prevalence estimates varied based on different screening tools. More observational studies assessing the mental wellness of COVID-19 outpatients and COVID-19 patients from countries other than China are needed to further examine the psychological implications of COVID-19 infections.

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: The Pooled Prevalence Of Depressionmentioning

confidence: 99%

Section: Subgroup Analysesmentioning

confidence: 99%

See 2 more Smart Citations

The prevalence of depression, anxiety, and sleep disturbances in COVID‐19 patients: a meta‐analysis

Deng

Zhou

Hou

et al. 2020

Annals of the New York Academy of Sciences

630

499

View full text Add to dashboard Cite

show abstract

“…During the COVID-19 pandemic, it has become apparent that a large number of visits can be managed on distance 213 , that the infrastructure for telemedicine is widely available 213,214 , and that the pandemic itself represents an opportunity to expand the use of telemedicine 215 . It has been reported that telepsychiatry may be efficient to screen for mental health symptoms in COVID-19 patients and to optimize treatment 216 , or that online assessments are helpful prior to appointments and as follow-up 217 . Continued care is, thus, enabled in a time when the health care systems are overwhelmed 218 .…”

Section: Telemedicine During the Covid-19 Pandemicmentioning

confidence: 99%

Adaptation of evidence‐based suicide prevention strategies during and after theCOVID‐19 pandemic

et al. 2020

View full text Add to dashboard Cite

Suicide is preventable. Nevertheless, each year 800,000 people die of suicide in the world. While there is evidence indicating that suicide rates de‐crease during times of crises, they are expected to increase once the immediate crisis has passed. The COVID‐19 pandemic affects risk and pro‐tective factors for suicide at each level of the socio‐ecological model. Economic downturn, augmented barriers to accessing health care, increased access to suicidal means, inappropriate media reporting at the societal level; deprioritization of mental health and preventive activities at the community level; interpersonal conflicts, neglect and violence at the relationship level; unemployment, poverty, loneliness and hopelessness at the individual level: all these variables contribute to an increase of depression, anxiety, post‐traumatic stress disorder, harmful use of alcohol, substance abuse, and ultimately suicide risk. Suicide should be prevented by strengthening universal strategies directed to the entire population, including mitigation of unemployment, poverty and inequalities; prioritization of access to mental health care; responsible media reporting, with information about available support; prevention of increased alcohol intake; and restriction of access to lethal means of suicide. Selective interventions should continue to target known vulnerable groups who are socio‐economically disadvantaged, but also new ones such as first responders and health care staff, and the bereaved by COVID‐19 who have been deprived of the final contact with loved ones and funerals. Indicated preventive strategies targeting individuals who display suicidal behaviour should focus on available pharmacological and psychological treatments of mental disorders, ensuring proper follow‐up and chain of care by increased use of telemedicine and other digital means. The scientific community, health care professionals, politicians and decision‐makers will find in this paper a systematic description of the effects of the pandemic on suicide risk at the society, community, family and individual levels, and an overview of how evidence‐based suicide preventive interventions should be adapted. Research is needed to investigate which adaptations are effective and in which con‐texts.

show abstract

Factors associated with progression of depression, anxiety, and stress‐related symptoms in outpatients and inpatients with COVID‐19: A longitudinal study

et al. 2022

View full text Add to dashboard Cite

It is known that there is an increase in the frequency of psychiatric disturbances in the acute and post‐illness phase of coronavirus disease (COVID‐19). Comorbid psychiatric symptoms complicate the management of patients and negatively affect the prognosis, but there is no clear evidence of their progress. We aimed to determine psychiatric comorbidity in inpatients and outpatients with COVID‐19 and recognize the factors that predict psychiatric comorbidity. For this purpose, we evaluated patients on the first admission and after 4 weeks. We investigated psychiatric symptoms in outpatients (n = 106) and inpatients (n = 128) diagnosed with COVID‐19. In the first 7 days after diagnosis (first phase), sociodemographic and clinic data were collected, a symptom checklist was constructed, and the Hospital Anxiety and Depression Scale (HADS) and the Severity of Acute Stress Symptoms Scale (SASSS) were applied. After 30–35 days following the diagnosis, the SASSS and the HADS were repeated. In the first phase, the frequency of depression and anxiety were 55% and 20% in inpatients, and 39% and 18% in outpatients, respectively. In the second phase, depression scores are significantly decreased in both groups whereas anxiety scores were decreased only in inpatients. The frequencies of patients reporting sleep and attention problems, irritability, and suicide ideas decreased after 1 month. Patients with loss of smell and taste exhibit higher anxiety and depression scores in both stages. Our results revealed that the rate of psychiatric symptoms in COVID‐19 patients improves within 1 month. Inpatients have a more significant decrease in both depression and anxiety frequency than do outpatients. The main factor affecting anxiety and depression was the treatment modality. Considering that all patients who were hospitalized were discharged at the end of the first month, this difference may be due to the elimination of the stress caused by hospitalization.

show abstract

A Report of the Telepsychiatric Evaluation of SARS-CoV-2 Patients

Cited by 40 publications

References 11 publications

The prevalence of depression, anxiety, and sleep disturbances in COVID‐19 patients: a meta‐analysis

The prevalence of depression, anxiety, and sleep disturbances in COVID‐19 patients: a meta‐analysis

Adaptation of evidence‐based suicide prevention strategies during and after theCOVID‐19 pandemic

Factors associated with progression of depression, anxiety, and stress‐related symptoms in outpatients and inpatients with COVID‐19: A longitudinal study

Contact Info

Product

Resources

About